Intellia Therapeutics (NTLA) Tops Q4 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
Intellia Therapeutics (NTLA) PT Lowered to $50 at Truist Securities
March 3, 2025 11:55 AM ESTTruist Securities analyst Joon Lee lowered the price target on Intellia Therapeutics (NASDAQ: NTLA) to $50.00 (from $90.00) while maintaining a Buy rating.
The analyst comments "4Q24: Restructuring underway should help extend operational runway into 1H27 as NTLA-2002 is poised to be the historic first in... More
